Pangaea Oncology, S.A. reported earnings results for the half year ended June 30, 2022. For the half year, the company reported sales was EUR 1.1 million compared to EUR 0.951873 million a year ago. Net loss was EUR 0.927342 million compared to net income of EUR 0.094668 million a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.77 EUR | +1.14% | +4.12% | -3.80% |
May. 08 | Pangaea Oncology, S.A. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
2023 | Pangaea Oncology, S.A. Reports Earnings Results for the Half Year Ended June 30, 2023 | CI |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-3.80% | 58.34M | |
+24.74% | 47.54B | |
-0.47% | 41.96B | |
+43.96% | 41.55B | |
+25.40% | 30.36B | |
+17.96% | 27.61B | |
-4.47% | 28.7B | |
+50.73% | 14.7B | |
+42.56% | 13.51B | |
+1.46% | 12.34B |
- Stock Market
- Equities
- PANG Stock
- News Pangaea Oncology, S.A.
- Pangaea Oncology, S.A. Reports Earnings Results for the Half Year Ended June 30, 2022